Cardiovascular Revascularization Medicine
Volume 8, Issue 3 , Pages 175-182 , July 2007

Abciximab offers greater benefits to insulin-dependent diabetic patients undergoing coronary stent implantation

References 

  1. Norhammar A, Malmberg K, Diderholm E, Lagerqvist B, Lindahl B, Ryden L, et al. Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. J Am Coll Cardiol. 2004;43:585–591
  2. Flaherty JD, Davidson CJ. Diabetes and coronary revascularization. JAMA. 2005;293:1501–1508
  3. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among adults, 1999–2000. JAMA. 2002;288:1723–1727
  4. Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med. 2002;162:1867–1872
  5. López-Mínguez JR, Nogales JM, Morales A, Alonso R, González R, Merchán A. Clinical and angiographic follow-up in patients with Cypher or Taxus stents in populations with high percentage of trial-excluded lesions. Cardiovasc Revasc Med. 2005;6:92–98
  6. Lincoff AM, Califf RM, Moliterno DJ, Ellis SG, Ducas J, Kramer J, et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. N Engl J Med. 1999;341:319–327
  7. Marso SP, Lincoff AM, Ellis SG, Bhatt DL, Tanguay JF, Kleiman NS, et al. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus. Results of the Epistent diabetic substudy. Circulation. 1999;100:2477–2484
  8. Yang TH, Park SW, Hong MK, Park DW, Park KM, Kim YH, et al. Impact of diabetes mellitus on angiographic and clinical outcomes in the drug-eluting stents era. Am J Cardiol. 2005;96:1392–1398
  9. Kuchulakanti PK, Torguson R, Canos D, Rha SW, Chu WW, Clavijo L, et al. Impact of treatment of coronary artery disease with sirolimus-eluting stents on outcomes of diabetic and nondiabetic patients. Am J Cardiol. 2005;96:1100–1106
  10. Pache J, Kastrati A, Mehilli J, Gawaz M, Neumann FJ, Seyfarth M, et al. Clopidogrel therapy in patients undergoing coronary stenting: value of a high-loading-dose regimen. Catheter Cardiovasc Interv. 2005;55:436–441
  11. Kastrati A, Mehilli J, Schühlen H, Dirschinger J, Dotzer F, ten Berg JM, et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pre-treatment with clopidogrel. N Engl J Med. 2004;350:232–238
  12. Morice MC, Colombo A, Meier B, Serruys P, Tamburino C, Guagliumi G, et al. for the REALITY Trial Investigators Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA. 2006;295:895–904
  13. Finn AV, Palacios IF, Kastrati A, Gold HK, et al. Drug eluting stents for diabetes mellitus: a rush to judgment?. J Am Coll Cardiol. 2005;45:479–483
  14. Tarantini G, Briguori C, Stankovic G, Takagi T, Corvaja N, Di Mario C, et al. Insulin-treated diabetes mellitus and predictors of mid-term clinical outcome after percutaneous coronary interventions with stent implantation. Ital Heart J. 2003;4:843–849
  15. Nogales JM, Morales A, López-Mínguez JR, González R, Alonso RF, Jiménez et al. Factores que influyen en la supervivencia del paciente diabético tras intervencionismo coronario percutáneo [abstract]. Rev Esp Cardiol 2005;58(Supl 1):85,P561.
  16. Moussa I, Leon MB, Baim DS, O'Neill WW, Popma JJ, Buchbinder M, et al. Impact of sirolimus-eluting stents on outcome in diabetic patients : a SIRIUS substudy. Circulation. 2004;109:2274–2278
  17. Karvouni E, Katritsis DG, Ioannidis JP. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. J Am Coll Cardiol. 2003;41:26–32
  18. Bhatt DL, Marso SP, Lincoff AM, Wolski KE, Ellis SG, Topol EJ. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol. 2000;35:922–928
  19. Tang WH, Lincoff AM. Diabetes, coronary intervention, and platelet glycoprotein IIb/IIIa blockade. The triad revisited. Circulation. 2004;110:3618–3620
  20. O'Shea JC, Hafley GE, Greenberg S, Hasselblad V, Lorenz TJ, Kitt MM, et al. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention : the ESPRIT trial: a randomized controlled trial. JAMA. 2001;285:2468–2473
  21. Silver S, Albertsson P, Avilés FF, Gamici PG, Colombo A, Hamm C, et al. Guidelines for percutaneous coronary interventions. Eur Heart J. 2005;26:804–847
  22. Ikeda U, Hojo Y, Katsuki T, Shimada T, The Eraser Investigators . Acute platelet inhibition with abciximab does not reduce in-stent restenosis (Eraser Study). Circulation. 1999;100:799–806
  23. Chaves AJ, Sousa AGMR, Mattos LA, Abizaid A, Staico R, Feres F, et al. Volumetric analysis of in-stent intimal hyperplasia in diabetic patients treated with or without abciximab: results of the Diabetes Abciximab steNT Evaluation (DANTE) randomized trial. Circulation. 2004;109:861–866
  24. Hausleiter J, Kastrati A, Mehilli J, Schuhlen H, Pache J, Dotzer F, et al. A randomized trial comparing phosphorylcholine-coated stenting with balloon angioplasty as well as abciximab with placebo for restenosis reduction in small coronary arteries. J Intern Med. 2004;256(5):388–397
  25. Mehilli J, Kastrati A, Schuhlen H, Dibra A, Dotzer F, von Beckerath N, et al. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation. 2004;110:3627–3635
  26. Hernández García JM, Dominguez Franco A, Jiménez Navarro MF, Alonso Briales JH, Curiel Balsera E, Gomez JJ, et al. ¿El abciximab mejora el pronóstico de los diabéticos tras la intervención coronaria?. Rev Esp Cardiol. 2002;55:810–815
  27. Berger PB, Steinbul S. Clinical implications of percutaneous coronary intervention-clopidogrel in unstable angina to prevent recurrent events (PCI.CURE) study; a US perspective. Circulation. 2002;106:2284–2287
  28. Steinhubl SR, Berger PB, Mann JT, Fry ET, DeLago A, Wilmer C, et al. Clopidogrel for the reduction of events during observations. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411–2420
  29. Chaves AJ, Sousa AG. Letter regarding article by Mehilli et al, “Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel”. Circulation. 2005;111(21):e370;[author reply e370–1]
  30. López-Mínguez JR, Fuentes ME, Doblado M, Merchán A, Martínez A, González R, et al. Prognostic role of systemic hypertension and diabetes mellitus in patients with unstable angina undergoing coronary stenting. Rev Esp Cardiol. 2003;56(10):987–994
  31. Briguori C, Colombo A, Airoldi F, Focaccio A, Iakovou I, Cieffo A, et al. Sirolimus-eluting stent implantation in diabetic patients with multivessel coronary artery disease. Am Heart J. 2005;150:807–813
  32. Ong A, Aoki J, van Miegehem C, Rodriguez GA, Valgimigli M, Tsuchida K, et al. Comparison of short- (one month) and long- (twelve months) term outcomes of sirolimus- versus paclitaxel-eluting stents in 293 consecutive patients with diabetes mellitas (from the RESEARCH and T-SEARCH Registries). Am J Cardiol. 2005;96:358–362
  33. Sabaté M, Jiménez-Quevedo P, Angiolillo DJ, Gomez-Hospital JA, Alfonso F, Hernández-Antolín R, et al. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients. The Diabetes and Sirolimus-Eluting Stent trial. Circulation. 2005;112:2175–2183
  34. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315–1323
  35. Hermiller JB, Raizner A, Cannon L, Gurbel PA, Kutcher MA, Wong SC, et al. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus. The Taxus IV trial. J Am Coll Cardiol. 2005;45:1172–1179
  36. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy , Mann JT, et al. One-year clinical results with the slow release, polymer based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation. 2004;109:1942–1947
  37. Lansky AJ, Costa RA, Mintz GS, Tsuchiya Y, Midei M, Cox DA, et al. for the DELIVER clinical trial investigators Non-polymer-based paclitaxel coated coronary stents for the treatment of patients with de novo coronary lesions-angiographic follow-up of the DELIVER clinical trial. Circulation. 2004;109:1948–1954
  38. Teirstein PS, Kao J, Watkins M, Tannenbaum MA, Laufer N, Chang M, et al. Impact of platelet glycoprotein IIb/IIIa inhibition on the paclitaxel-eluting stent in patients with stable or unstable angina pectoris or provocable myocardial ischemia (A TAXUS IV substudy). Am J Cardiol. 2005;96:500–505
  39. Bonz AW, Lengenfelder B, Strotmann J, Held S, Turschener O, Harre K, et al. Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pre-treatment with aspirin and clopidogrel (TOPSTAR trial). J Am Coll Cardiol. 2002;40:662–668
  40. Lincoff AM, Keriakes DJ, Mascelli MA, Deckelbaum LI, Barnathan ES, Patel KK, et al. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation. 2001;104:163–167
  41. Applegate RJ, Upadhya B, Little WC, Xenakis M, Ghandi SK, Baki TT, et al. Late outcomes after intervention of vein grafts in diabetics with abciximab use. Int J Cardiol. 2006;111:136–141

PII: S1553-8389(07)00047-4

doi: 10.1016/j.carrev.2007.03.005

Cardiovascular Revascularization Medicine
Volume 8, Issue 3 , Pages 175-182 , July 2007

Article Tools

* Image Usage & Resolution